Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
The pharmaceutical industry strongly opposes a simple expansion of the current rule to deduct the price maintenance premium (PMP) from PMP-granted comparator drugs in the pricing of new medicines deemed PMP-ineligible, but might accept such deduction if no PMP-eligible indications…
To read the full story
Related Article
- “Third Price Revision” Eyed for Expansion of Comparator PMP Deduction Rule
December 11, 2019
- Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
- US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
REGULATORY
- Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
- Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…